MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:33Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Calcium channel blockers]]
			[[Category:Antihypertensives]]
			[[Category:Antianginals]]
			[[Category:Tocolytics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #120

2026-05-23T03:51:55Z

parser-claude batch MedTemplate pre-fill, Top 300 #120

New page

{{MedTemplate
| generic = Nifedipine
| brand = Procardia, Procardia XL, Adalat CC, Afeditab CR
| structure =
| classes = [[:Category:Calcium_channel_blockers|Calcium channel blocker (dihydropyridine)]], [[:Category:Antihypertensives|Antihypertensive]], [[:Category:Antianginals|Antianginal]], [[:Category:Tocolytics|Tocolytic (off-label)]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="vasospastic-angina-use">Vasospastic (Prinzmetal) angina</vote>, <vote slug="stable-angina-use">Stable angina</vote>, <vote slug="severe-hypertension-pregnancy-use">Severe hypertension in pregnancy (oral)</vote>, <vote slug="preterm-labor-tocolysis-use">Preterm labor (off-label tocolysis)</vote>, <vote slug="raynaud-use">Raynaud's phenomenon</vote>
| starting_dose = ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia)
| preparations = 10, 20 mg IR capsules; 30, 60, 90 mg ER tablets
| fda_max = 120 mg/d (ER); IR not for chronic hypertension
| pill_id =
| routes = Oral; sublingual IR is discouraged (uncontrolled BP drops, MI reports)
| onset = IR 20 minutes; ER ~6 hours
| duration = IR 4-8 hours; ER 24 hours
| halflife = 2-5 hours (IR); ER formulations extend functional duration via osmotic/matrix release<ref name="procardia-label">FDA Prescribing Information, Procardia XL (nifedipine), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018612s045lbl.pdf</ref>
| bioavailability = ~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited<ref name="procardia-label" />
| pregnancy = Oral nifedipine is one of the preferred agents for severe hypertension in pregnancy and for tocolysis in preterm labor.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="nifedipine-mech-claim">Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type voltage-gated calcium channels in vascular smooth muscle, producing peripheral and coronary arterial vasodilation; cardiac myocyte and AV nodal effects are minimal compared with non-dihydropyridines like diltiazem and verapamil.</vote> Immediate-release nifedipine's rapid vasodilation and reflex sympathetic activation drove the early 1990s safety concerns that led to ER-only chronic use; sublingual IR is contraindicated. CYP3A4 substrate with substantial grapefruit/itraconazole interactions<ref name="procardia-label" />.
}}

== References ==
<references />

Nifedipine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #120